Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745803 | 0.82 | KCNH2 (0.35) | KCNH2CYP2C8CYP2C9MAT2AMAPT | |
| SCHEMBL3923721 | 0.81 | FADS1 (0.31) | — | |
| SCHEMBL4489281 | 0.80 | KCNH2 (0.34) | KCNH2CYP2C8CYP2C9HTTSMN1; SMN2 | |
| SCHEMBL4877684 | 0.74 | MAT2A (0.39) | KCNH2MAT2AMAPTMAPK1HTT | |
| SCHEMBL3986451 | 0.73 | JAK2 (0.36) | MAT2ANPSR1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4492304 | 0.73 | ACLY (0.31) | — | |
| SCHEMBL4481630 | 0.73 | ACLY (0.31) | — | |
| SCHEMBL4485590 | 0.72 | TP53 (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL3993899 | 0.72 | TP53 (0.33) | MAPTSMN1; SMN2 | |
| SCHEMBL3989442 | 0.70 | NPBWR1 (0.41) | CYP2C9MAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2009-07-23 | — | — | US | disclosed |
| EP-2034993-A2 | PYRAZINONES AS CELLULAR PROLIFERATION INHIBITORS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007149448-A2 | PYRAZINONES AS CELLULAR PROLIFERATION INHIBITORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186907-A1 | Pyrazinones As Cellular Proliferation Inhibitors | MKI67, NR0B1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | KCNH2 1274/4885CYP2C8 170/4885CYP2C9 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.